MedTrace Logo

Safety/Tolerability and Pharmacokinetic Study of SID142

NCT02625714 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2015-12-14

No results posted yet for this study

Summary

A randomized, open-label, oral multiple dosing, two-part, two-way crossover clinical trial to evaluate the safety/tolerability and pharmacokinetic profiles of SID142 in healthy volunteers

Conditions

  • Arterial Occlusive Diseases

Interventions

DRUG

Renexin®

Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid

DRUG

SID142

Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min Kyu Park, MD,PhD · Dong-A University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-07-31
Completion
2015-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02625714 on ClinicalTrials.gov